What does Will - Pharma do?

Will - Pharma is registered with the CBE as active in: Vervaardiging van geneesmiddelen. Public Limited, started on 7 October 1960, 2 establishments.

What is the address of Will - Pharma?

The registered office of Will - Pharma is located at Rue du Manil 80, 1301 Wavre.

Is Will - Pharma still active?

Yes. According to the CBE (29 October 2026) Will - Pharma is active, legal situation “Normale toestand”, started on 7 October 1960.

Is Will - Pharma registered on Peppol?

Yes, Will - Pharma is registered on the Peppol network with ID 0208:0402018775.

What is the enterprise number of Will - Pharma?

The enterprise number of Will - Pharma is BE0402018775.

When was Will - Pharma founded?

Will - Pharma was founded on 7 October 1960.

Who are the directors of Will - Pharma?

According to the 2025 annual accounts, the directors of Will - Pharma are: Daniel DELATTE, MAGILITY SRL.

Is Will - Pharma a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 7 October 1960; 5 annual accounts filed, latest fiscal year 2025; 2 directors known from the annual account; 2 establishments in the CBE.

How much profit did Will - Pharma make in 2025?

Will - Pharma posted a profit after taxes of € 358,166 in financial year 2025.

What is the revenue of Will - Pharma?

In its most recent annual accounts (2025), Will - Pharma reported revenue of € 17,801,611.

How much does an employee at Will - Pharma earn?

The average wage cost per full-time employee at Will - Pharma was € 103,700 in 2025: staff costs of € 2.8 million for 27.1 FTE, according to the annual account at the National Bank. That is the employer's cost, not net pay.

How many employees does Will - Pharma have?

According to the 2025 annual accounts, Will - Pharma has 27.1 full-time equivalents (FTE).

Will - Pharma (Public Limited) - Wavre - BE0402018775

Dossier Will - Pharma, printed on 29 October 2026 from databakkes.be/en/0402018775/will-pharma. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Financials

Financial year 2025

Will - Pharma from Wavre, company number BE0402018775, closed financial year 2025 with a result of € 358,166 after tax. For that financial year Will - Pharma recorded revenue of € 17.8 million and equity of € 4.7 million. Compared with financial year 2024, the result moved from € 310,424 to € 358,166. Profitable, and profit is growing. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on July 6, 2026.

What it is worth Growing

€ 4.7 million

▲ 8% vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Profit Growing

€ 358,166

▲ 15% vs 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 1.5 million

▲ 176% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Growing

Stays in the company

No dividend for 2025. Retained profit grew to € 1.7 million.

People and assets in 2025

Full-time equivalents

27.1

▲ 0.4 vs 2024

Average over the fiscal year, from the social balance sheet.

Wage cost Staff costs are payroll only. Director pay sits with services and miscellaneous goods: € 7.1 million in 2025, together with rent, insurance, accountants and other services. The accounts do not split that further.

€ 2.8 million

▲ 9% vs 2024

€ 103,700 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.

Vehicles and equipment

€ 31,941

▼ 10% vs 2024

Book value of vehicles, furniture and equipment.

Debts at end 2025

Bank debt

None

No bank loans on the last day of the fiscal year.

Owed to suppliers

€ 3 million

▲ 7% vs 2024

Supplier invoices still open on the last day of the fiscal year. Pays suppliers within 79 days on average.

Taxes and wages

€ 650,485

▲ 29% vs 2024

Taxes, VAT and social contributions still to pay.

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Revenue	€ 15,863,971 Revenue 2022: € 15,863,971 First fiscal year in the series	€ 15,721,658 Revenue 2023: € 15,721,658 ▼ 1% vs 2022 (€ 15,863,971) Unfavourable step	€ 16,250,726 Revenue 2024: € 16,250,726 ▲ 3% vs 2023 (€ 15,721,658) Favourable step	€ 17,801,611 Revenue 2025: € 17,801,611 ▲ 10% vs 2024 (€ 16,250,726) Favourable step	▲ 10%
Profit after taxes	€ 266,337 Profit after taxes 2022: € 266,337 First fiscal year in the series	€ 299,758 Profit after taxes 2023: € 299,758 ▲ 13% vs 2022 (€ 266,337) Favourable step	€ 310,424 Profit after taxes 2024: € 310,424 ▲ 4% vs 2023 (€ 299,758) Favourable step	€ 358,166 Profit after taxes 2025: € 358,166 ▲ 15% vs 2024 (€ 310,424) Favourable step	▲ 15%
Equity	€ 8,696,099 Equity 2022: € 8,696,099 First fiscal year in the series	€ 3,995,856 Equity 2023: € 3,995,856 ▼ 54% vs 2022 (€ 8,696,099) Unfavourable step	€ 4,306,280 Equity 2024: € 4,306,280 ▲ 8% vs 2023 (€ 3,995,856) Favourable step	€ 4,664,446 Equity 2025: € 4,664,446 ▲ 8% vs 2024 (€ 4,306,280) Favourable step	▲ 8%
Total debts	€ 9,156,276 Total debts 2022: € 9,156,276 First fiscal year in the series	€ 5,373,984 Total debts 2023: € 5,373,984 ▼ 41% vs 2022 (€ 9,156,276) Favourable step	€ 4,650,406 Total debts 2024: € 4,650,406 ▼ 13% vs 2023 (€ 5,373,984) Favourable step	€ 5,028,001 Total debts 2025: € 5,028,001 ▲ 8% vs 2024 (€ 4,650,406) Unfavourable step	▲ 8%
Cash	€ 1,681,149 Cash 2022: € 1,681,149 First fiscal year in the series	€ 1,645,456 Cash 2023: € 1,645,456 ▼ 2% vs 2022 (€ 1,681,149) Unfavourable step	€ 557,429 Cash 2024: € 557,429 ▼ 66% vs 2023 (€ 1,645,456) Unfavourable step	€ 1,535,863 Cash 2025: € 1,535,863 ▲ 176% vs 2024 (€ 557,429) Favourable step	▲ 176%
Land & buildings	€ 360,658 Land & buildings 2022: € 360,658 First fiscal year in the series	€ 378,333 Land & buildings 2023: € 378,333 ▲ 5% vs 2022 (€ 360,658) Unchanged	€ 389,120 Land & buildings 2024: € 389,120 ▲ 3% vs 2023 (€ 378,333) Unchanged	€ 344,421 Land & buildings 2025: € 344,421 ▼ 11% vs 2024 (€ 389,120) Unchanged	▼ 11%
Retained profit	€ 5,687,117 Retained profit 2022: € 5,687,117 First fiscal year in the series	€ 986,875 Retained profit 2023: € 986,875 ▼ 83% vs 2022 (€ 5,687,117) Unfavourable step	€ 1,297,299 Retained profit 2024: € 1,297,299 ▲ 31% vs 2023 (€ 986,875) Favourable step	€ 1,655,465 Retained profit 2025: € 1,655,465 ▲ 28% vs 2024 (€ 1,297,299) Favourable step	▲ 28%
Dividend	€ 0 Dividend 2022: € 0 First fiscal year in the series	€ 5,000,000 Dividend 2023: € 5,000,000 Unchanged (€ 0) Unchanged	€ 0 Dividend 2024: € 0 ▼ 100% vs 2023 (€ 5,000,000) Unchanged	€ 0 Dividend 2025: € 0 Unchanged (€ 0) Unchanged
Bank debt	€ 1,100,000 Bank debt 2022: € 1,100,000 First fiscal year in the series	€ 0 Bank debt 2023: € 0 ▼ 100% vs 2022 (€ 1,100,000) Favourable step	€ 0 Bank debt 2024: € 0 Unchanged (€ 0) Unchanged	€ 0 Bank debt 2025: € 0 Unchanged (€ 0) Unchanged
Balance sheet total	€ 17,946,369 Balance sheet total 2022: € 17,946,369 First fiscal year in the series	€ 9,471,857 Balance sheet total 2023: € 9,471,857 ▼ 47% vs 2022 (€ 17,946,369) Unchanged	€ 9,008,775 Balance sheet total 2024: € 9,008,775 ▼ 5% vs 2023 (€ 9,471,857) Unchanged	€ 9,729,558 Balance sheet total 2025: € 9,729,558 ▲ 8% vs 2024 (€ 9,008,775) Unchanged	▲ 8%
Employees (FTE)	25.7 Employees (FTE) 2022: 25.7 First fiscal year in the series	24.4 Employees (FTE) 2023: 24.4 ▼ 1.3 vs 2022 (25.7) Unchanged	26.7 Employees (FTE) 2024: 26.7 ▲ 2.3 vs 2023 (24.4) Unchanged	27.1 Employees (FTE) 2025: 27.1 ▲ 0.4 vs 2024 (26.7) Unchanged	▲ 0.4

Key figures of Will - Pharma, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to Will - Pharma?

What happened at Will - Pharma in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

2030 MAGILITY SRL stepped down as director. NBB
Jul 6, 2026 New annual accounts for financial year 2025: profit of € 358,166 (▲ 15% vs 2024). Source: NBB ↗
2026 Daniel DELATTE stepped down as director. NBB
2024 MAGILITY SRL became a director. NBB
Aug 1, 2012 New establishment in Wavre. KBO
Jul 27, 1971 New establishment in Wavre. KBO
Oct 7, 1960 Start of the company according to the CBE. KBO

In short

From € 266,337 profit in 2022 to € 358,166 profit in 2025.

Paid € 654,600 in corporate taxes since 2022.

Best year ever: 2025, with € 358,166 profit.

Paid out € 5 million in dividends to the owners in total.

Original PDFs at the National Bank ↗

Management

DEPHARM 100%

The stake of DEPHARM comes from that shareholder’s own annual accounts; small companies do not report their shareholders themselves.

Will - Pharma

The shares are held by DEPHARM (100%).

Directors

According to the 2025 annual accounts

Daniel DELATTE

Director

Also active at: L.F. Will et Cie, CENTRE DE CARDIOLOGIE DES STATUAIRES

· until 2026

MAGILITY SRL

Director · represented by MAURIENNE WILL

Also active at: L.F. Will et Cie, DEPHARM

since 2024 · until 2030

Shareholders

DEPHARM

100%

Participations

No participations in other companies reported.

Establishments

Establishment units

Physical locations of this company

Registered office

Rue du Manil 80

1301 Wavre

2.212.120.632

Boulevard de l'Europe 123-125

1300 Wavre

Active since 1 August 2012

Who else lives here?

A building full of entrepreneurs or one very busy letterbox? Another 4 companies are registered at this address.

All companies at this address →

L.F. Will et Cie same network

DEPHARM same network

€ 1.2 million revenue · 2025

DURONDO

M.V.V.M.

€ -853 gross margin · 2025

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number: 0402.018.775
VAT number: BE 0402.018.775
Registered office: Rue du Manil 80, 1301 Wavre
Names & denominations: Will - Pharma
Enterprise type: Rechtspersoon
Legal form: Public limited company
Legal situation: Normale toestand
Start date: 7 October 1960
Peppol: Active · Active since 31 Dec 2025
Activities · NACE: Vervaardiging van geneesmiddelen

View on CBE Public ↗ Annual accounts (NBB) ↗